210 related articles for article (PubMed ID: 22050952)
1. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
[TBL] [Abstract][Full Text] [Related]
2. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
3. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz G; Harrer A; Oppermann K; Wipfler P; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Mult Scler; 2012 Apr; 18(4):506-9. PubMed ID: 21965415
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R
Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
6. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver B; Fernández O; Orpez T; Alvarenga MP; Pinto-Medel MJ; Guerrero M; León A; López-Madrona JC; Maldonado-Sánchez R; García-León JA; Luque G; Fernández V; Leyva L
Mult Scler; 2011 Mar; 17(3):368-71. PubMed ID: 21177326
[TBL] [Abstract][Full Text] [Related]
9. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab effects on immune cell responses in multiple sclerosis.
Niino M; Bodner C; Simard ML; Alatab S; Gano D; Kim HJ; Trigueiro M; Racicot D; Guérette C; Antel JP; Fournier A; Grand'Maison F; Bar-Or A
Ann Neurol; 2006 May; 59(5):748-54. PubMed ID: 16634035
[TBL] [Abstract][Full Text] [Related]
11. Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I; Hellwig K; Berthele A; Kümpfel T; Linker RA; Hartung HP; Paul F; Aktas O;
Arch Neurol; 2012 Feb; 69(2):239-45. PubMed ID: 22332191
[TBL] [Abstract][Full Text] [Related]
12. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
[TBL] [Abstract][Full Text] [Related]
13. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
[TBL] [Abstract][Full Text] [Related]
14. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
Tasset I; Aguera E; Gascon F; Giraldo AI; Salcedo M; Cruz AH; Sanchez F; Tunez I
Rev Neurol; 2012 Apr; 54(8):449-52. PubMed ID: 22492096
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
16. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
17. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.
Papeix C; Depaz R; Tourbah A; Stankoff B; Lubetzki C
Mult Scler; 2011 Dec; 17(12):1520-2. PubMed ID: 21669937
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
